Chau Thach

2.3k total citations · 1 hit paper
26 papers, 1.7k citations indexed

About

Chau Thach is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Chau Thach has authored 26 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 10 papers in Physiology and 8 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Chau Thach's work include Chronic Obstructive Pulmonary Disease (COPD) Research (14 papers), Asthma and respiratory diseases (10 papers) and Respiratory and Cough-Related Research (8 papers). Chau Thach is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (14 papers), Asthma and respiratory diseases (10 papers) and Respiratory and Cough-Related Research (8 papers). Chau Thach collaborates with scholars based in United States, Switzerland and United Kingdom. Chau Thach's co-authors include Donald Banerji, Francesco Patalano, Robert Fogel, Abraham A. Ariyo, Russell P. Tracy, Jadwiga A. Wedzicha, Kenneth R. Chapman, Claus Vogelmeier, Nicolás Roche and Jørgen Vestbo and has published in prestigious journals such as New England Journal of Medicine, Circulation and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Chau Thach

25 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD

2016 547 citations Jadwiga A. Wedzicha, Donald Banerji et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chau Thach United States	13	1.0k	794	294	289	256	26	1.7k
Bradley J. Maroni United States	26	268 0.3×	839 1.1×	328 1.1×	181 0.6×	149 0.6×	41	3.1k
Ryo Naito Japan	24	237 0.2×	368 0.5×	676 2.3×	853 3.0×	218 0.9×	112	1.7k
Prabhleen Singh United States	24	292 0.3×	224 0.3×	352 1.2×	148 0.5×	326 1.3×	39	1.6k
H Wilkes United Kingdom	13	558 0.5×	124 0.2×	197 0.7×	359 1.2×	251 1.0×	16	1.3k
Jacek Manitius Poland	19	158 0.2×	297 0.4×	190 0.6×	309 1.1×	505 2.0×	122	1.8k
Gursharan Dogra Australia	22	249 0.2×	107 0.1×	291 1.0×	330 1.1×	228 0.9×	42	1.4k
Noritake Hata Japan	23	409 0.4×	132 0.2×	403 1.4×	995 3.4×	106 0.4×	126	1.7k
Christian Jonasson Norway	19	263 0.3×	224 0.3×	502 1.7×	332 1.1×	645 2.5×	39	1.6k
Angela Scozzafava Italy	7	165 0.2×	272 0.3×	134 0.5×	742 2.6×	174 0.7×	7	1.1k
Mihai Gheorghiade United States	22	578 0.6×	188 0.2×	348 1.2×	1.9k 6.7×	266 1.0×	43	2.6k

Countries citing papers authored by Chau Thach

Since Specialization

Citations

This map shows the geographic impact of Chau Thach's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chau Thach with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chau Thach more than expected).

Fields of papers citing papers by Chau Thach

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chau Thach. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chau Thach. The network helps show where Chau Thach may publish in the future.

Co-authorship network of co-authors of Chau Thach

This figure shows the co-authorship network connecting the top 25 collaborators of Chau Thach. A scholar is included among the top collaborators of Chau Thach based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chau Thach. Chau Thach is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Leidy, Nancy Kline, et al.. (2022). Interpreting Evaluating Respiratory Symptoms™ in COPD Diary Scores in Clinical Trials: Terminology, Methods, and. Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation. 9(4). 576–590. 2 indexed citations

Bushnell, Donald M., Rozanne Wilson, F Gutzwiller, et al.. (2021). Use of the Evaluating Respiratory Symptoms™ in COPD as an Outcome Measure in Clinical Trials: A Rapid Systematic Review. Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation. 8(4). 551–571. 4 indexed citations

Vogelmeier, Claus, Kenneth R. Chapman, Marc Miravitlles, et al.. (2018). Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study. International Journal of COPD. Volume 13. 1125–1134. 12 indexed citations

Roche, Nicolás, Kenneth R. Chapman, Claus Vogelmeier, et al.. (2017). Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial. American Journal of Respiratory and Critical Care Medicine. 195(9). 1189–1197. 116 indexed citations

Wedzicha, Jadwiga A., Nanshan Zhong, Masakazu Ichinose, et al.. (2017). Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study. International Journal of COPD. Volume 12. 339–349. 30 indexed citations

Wedzicha, Jadwiga A., Claus Vogelmeier, Tim Ayers, et al.. (2017). Respiratory safety profile of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC): results from the FLAME study. PA1075–PA1075. 1 indexed citations

Wedzicha, Jadwiga A., Donald Banerji, Kenneth R. Chapman, et al.. (2016). Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD. New England Journal of Medicine. 374(23). 2222–2234. 547 indexed citations breakdown →

Ferguson, Gary T., et al.. (2016). Long-Term Maintenance Bronchodilation With Indacaterol/Glycopyrrolate Versus Indacaterol in Moderate-to-Severe COPD Patients: The FLIGHT 3 Study. Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation. 3(4). 716–728. 15 indexed citations

Mahler, Donald A., Edward Kerwin, Tim Ayers, et al.. (2015). FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. 192(9). 1068–1079. 94 indexed citations

10.

Sannigrahi, Santanu, Changzheng Wang, Xiangdong Zhou, et al.. (2015). LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. International Journal of COPD. 10. 1015–1015. 132 indexed citations

11.

Shah, Sukrut, Anne Hermanowski‐Vosatka, D. Plotkin, et al.. (2011). Effects of an 11 β ‐hydroxysteroid dehydrogenase type 1 inhibitor, MK‐0916, in patients with type 2 diabetes mellitus and metabolic syndrome. Diabetes Obesity and Metabolism. 13(6). 498–504. 132 indexed citations

12.

Thach, Chau, et al.. (2007). Effects of Etoricoxib and Comparator Nonsteroidal Anti‐Inflammatory Drugs on Urinary Sodium Excretion, Blood Pressure, and Other Renal Function Indicators in Elderly Subjects Consuming a Controlled Sodium Diet. The Journal of Clinical Pharmacology. 47(12). 1521–1531. 16 indexed citations

13.

Hecken, A. Van, Inge De Lepeleire, Chau Thach, et al.. (2007). The effect of MK-0524, a prostaglandin D2 receptor antagonist, on prostaglandin D2-induced nasal airway obstruction in healthy volunteers. European Journal of Clinical Pharmacology. 63(2). 135–141. 29 indexed citations

14.

Thach, Chau, et al.. (2004). Lp(a) lipoprotein, vascular disease, and mortality in the elderly. Journal of Vascular Surgery. 39(4). 921–921. 1 indexed citations

15.

Ariyo, Abraham A., Chau Thach, & R. E. Tracy. (2004). Lp (a) lipoprotein, vascular disease and mortality in the elderly. ACC Current Journal Review. 13(3). 25–25. 1 indexed citations

16.

Ariyo, Abraham A., Chau Thach, & Russell P. Tracy. (2003). Lp(a) Lipoprotein, Vascular Disease, and Mortality in the Elderly. New England Journal of Medicine. 349(22). 2108–2115. 215 indexed citations

17.

Thach, Chau, et al.. (2003). C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly. ACC Current Journal Review. 12(6). 24–25. 35 indexed citations

18.

Thach, Chau & Lloyd D. Fisher. (2002). Self-Designing Two-Stage Trials to Minimize Expected Costs. Biometrics. 58(2). 432–438. 10 indexed citations

19.

Carr, Darcy B., George B. McDonald, Debra Brateng, et al.. (2001). The Relationship Between Hemodynamics and Inflammatory Activation in Women at Risk for Preeclampsia. Obstetrics and Gynecology. 98(6). 1109–1116. 7 indexed citations

20.

Augustovski, Federico, Scott B. Cantor, Chau Thach, & Stephen J. Spann. (1998). Aspirin for primary prevention of cardiovascular events. Journal of General Internal Medicine. 13(12). 824–835. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact